Drug and Therapeutics Bulletin 2008;46:57-61; doi:10.1136/dtb.2008.07.0017
Copyright © 2008 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
PubMed
Right arrow PubMed Citation

Rituximab and {blacktriangledown}abatacept for rheumatoid arthritis

Relevant BNF section: 10.1.3

Estimates from the UK indicate that around 0.5–1.0% of the population have rheumatoid arthritis.1 Here we assess the place of rituximab (MabThera – Roche Products Ltd) and {blacktriangledown}abatacept (Orencia – Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2008 BMJ Publishing Group Ltd.